News Results
There are 371,737 News Results
Feb 25, 2025
SAN JOSE, Calif. , Feb. 25, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK) ("QuickLogic" or the "Company"), a developer of embedded FPGA (eFPGA) IP, ruggedized FPGAs and Endpoint AI solutions,...
Feb 26, 2025
Increases net subscriber-add expectations for 2025 significantly to 180-200,000, expecting to reach 2.6 million subscribers by year-end;
Feb 27, 2025
-- Achieved Q4 2024 GAAP Net Income of $3.6 million -- Generated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-year -- Delivered full-year 2024 adjusted EBITDA of $8.6...
Mar 3, 2025
Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million
Mar 5, 2025
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors-
Mar 13, 2025
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
-- Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand potential access and...
Mar 20, 2025
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory patients has expanded its reach....
Mar 21, 2025
TEL AVIV, Israel, March 21, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned aircrafts and...
Mar 26, 2025
Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMG(a) score in antibody positive adult patients:...
Mar 31, 2025
FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU
